Skip to main content

Table 3 Change in baseline to endpoint in depressive symptomatology and psychosocial functioning

From: The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial

Measure characteristic

Baseline

Fluoxetinea Endpoint

Change

Baseline

Placebob Endpoint

Change

Difference in Changec

(95% CI)

pd

F

CDRS-R

53.0 ± 2.32

34.60 ± 3.22

-18.40 ± 2.94

53.94 ± 2.46

31.31 ± 3.42

-22.63 ± 3.12

-4.23

(-12.95–4.49)

.33

0.98

CGI-S

4.28 ± 0.15

2.88 ± 0.28

-1.39 ± 0.28

4.37 ± 0.16

2.87 ± 0.30

-1.50 ± 0.30

-0.11

(-0.95–0.73)

.71

0.07

CGI-I

--

2.61 ± 0.32

--

--

2.44 ± 0.34

--

-0.17

(-1.12–0.77)

.79

0.14

BDI

17.20 ± 3.10

7.62 ± 1.96

-9.58 ± 3.29

13.00 ± 3.33

8.12 ± 2.11

-4.88 ± 3.54

4.70

(-5.23–14.63)

.34

0.95

BHS

7.33 ± 1.38

4.07 ± 1.10

-3.27 ± 1.38

7.69 ± 1.49

5.46 ± 1.18

-2.23 ± 1.48

1.04

(-3.12–5.19)

.61

0.26

CGAS

53.06 ± 2.06

69.63 ± 3.62

16.56 ± 3.50

51.21 ± 2.20

65.93 ± 3.87

14.71 ± 3.75

1.85

(-8.67–12.37)

.72

0.13

  1. Values represent mean ± SE from fixed effects parameter estimates. CDRS-R = Children's Depression Rating Scale-Revised; CGI-S = Clinical Global Impressions – Severity scale; CGI-I = Clinical Global Impressions – Improvement Scale; BDI = Beck Depression Inventory; BHS=Beck Hopelessness Scale; CGAS = Children's Global Assessment of Functioning
  2. aFluoxetine: last observation carried forward: for BDI, n = 15, for BHS, n = 15, for CGAS, n = 16.
  3. bPlacebo: last observation carried forward: for BDI, n = 13, for BHS, n = 13, for CGAS, n = 14.
  4. cDifference in Change shows the difference in average change score of fluoxetine-treated patients in comparison to placebo-treated patients. The 95% confidence intervals for the differences are shown in parentheses below. If the entire 95% confidence interval is greater than zero, this indicates a 95% or greater probability that the mean change associated with fluoxetine treatment is greater than the mean change associated with placebo.
  5. dGeneralized linear model (GLM) procedures were used for analysis of continuous baseline and endpoint values; Value for difference in mean change between treatment groups, using Type III difference of least square means.